Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Michael R Narkewicz

2PUBLICATIONS

3CO-AUTHORS

Carbon capture engineering (excl. sequestration)Occupational epidemiology

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (2)

Sort by Publication Date:

|Feb 19, 2026

The Impact of Elexacaftor-Tezacaftor-Ivacaftor on Biochemical Surrogates of Cystic Fibrosis Hepatobiliary Involvement: A Retrospective Cohort Study.

Sasha-Jane Abi-Aad, Athanasios Tsalatsanis, Michael Narkewicz

|Nov 26, 2025

Impact of elexacaftor/tezacaftor/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study.

Wen Ye, John C Magee, Suiyuan Huang

Pageof 1

Frequent Collaborators

1 joint publications

Sasha-Jane Abi-Aad

1 joint publications

Athanasios Tsalatsanis

1 joint publications

Racha T Khalaf

Frequent Collaborators

1 joint publications

Sasha-Jane Abi-Aad

1 joint publications

Athanasios Tsalatsanis

1 joint publications

Racha T Khalaf

Top Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on : Oct 15, 2017

See more related videos

Top Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on : Oct 15, 2017

See more related videos